Skip to main content
. 2023 Apr 27;14:1145441. doi: 10.3389/fimmu.2023.1145441

Figure 7.

Figure 7

The anti-tumor ability of Dec or Aza pretreated CD44v6 CAR-T against Dec and Aza pretreated AML in vitro and in vivo. (A) Cytotoxicity of Dec (left) and Aza (right) pretreated CD44v6 CAR-T (dCAR-T, aCAR-T, n=6) to MV4-11 cells pretreated with or without Dec and Aza in an E:T ratio of 10:1 for 24 h. (B) Schematic of Dec pretreated CD44v6 CAR-T treatment of Dec pretreated MV4-11 cells xenografts mice. BALB/c-nu mice were subcutaneously injected with 5×106 MV4-11-firefly luciferase (Luc+ MV4-11) cells on day 0. Dec 1 mg/kg or 100 μl PBS were intraperitoneally injected on day 7, 8, 9, 14, 15 and 16. Then dCAR-T cells (5×106) were intratumorally injected on day 10 and day 17. Tumor burden was analyzed by BLI on days 7, 14, 21 and 28. (C, D) Graph (C) and BLI images (D) showing the progress of tumor burden at the indicated time point. dCAR-T: Dec pretreated CD44v6 CAR-T; aCAR-T: Aza pretreated CD44v6 CAR-T. Data are depicted as the mean± SD. *p<.05; ns, not significant.